151
Participants
Start Date
December 10, 2019
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2022
Warfarin
Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
Apixaban
Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
No oral anticoagulation
No oral anticoagulation
Prince of Wales Hospital, Randwick
Royal North Shore Hospital, Saint Leonards
Nepean Hospital, Kingswood
St. George Hospital, Sydney
The Ottawa Hospital - Riverside Campus, Ottawa
Surrey Memorial Hospital, Surrey
St. Paul's Hospital, Vancouver
Seven Oaks General Hospital, Winnipeg
Nova Scotia Health Authority, QEII Health Sciences Centre, Halifax
Royal Victoria Regional Health Centre, Barrie
Health Sciences North, Greater Sudbury
St. Joseph's Healthcare Hamilton, Hamilton
Kingston Health Sciences Centre - Kingston General Hospital, Kingston
London Health Sciences Centre, London
Halton Healthcare - Oakville Trafalgar Memorial Hospital, Oakville
Lakeridge Health Oshawa, Oshawa
Thunder Bay Regional Health Sciences Centre, Thunder Bay
Sunnybrook Health Sciences Centre, Toronto
Unity Health Toronto, at its St. Michael's Hospital site, Toronto
University Health Network - Toronto General Hospital, Toronto
St. Joseph's Health Centre Toronto, Toronto
Hôpital Maisonneuve-Rosemont, Montreal
Centre Hospitalier de l'Université de Montréal, Montreal
Jewish General Hospital, Montreal
Hôpital du Sacré-Cœur de Montréal, Montreal
McGill University Health Centre, Montreal
CHU de Québec - Université Laval, Québec
Regina General Hospital, Regina
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
The George Institute for Global Health (Sydney, Australia)
UNKNOWN
Unity Health Toronto
OTHER